path(MESH:D005221) association a(MESH:D002800)

View Subject View Object

PubMed:18986241

Since the cholinergic deficit is not an early defect in the progression of AD [18–20], the use of these drugs in the prodromal stages of AD should be continued. However, the limited effect of cholinesterase inhibitors for the treatment of cognitive decline in AD coupled with unwanted side effects such as diarrhea, nausea, insomnia, fatigue and loss of appetite indicates the need to move beyond this conventional drug treatment with somewhat circumscribed efficacy.

Related Edges 9

• a(MESH:D002800) association path(MESH:D007319)
• a(MESH:D002800) association path(MESH:D003967)
• a(MESH:D002800) association path(MESH:D009325)
• a(MESH:D002800) association path(MESH:D005221)
• a(MESH:D002800) association path(MESH:D000855)
• path(MESH:D000855) association a(MESH:D002800)
• path(MESH:D003967) association a(MESH:D002800)
• path(MESH:D007319) association a(MESH:D002800)
• path(MESH:D009325) association a(MESH:D002800)

Disease Ontology (DO)

Alzheimer's disease

MeSH

Cognitive Dysfunction

BEL Commons is developed and maintained in an academic capacity by Charles Tapley Hoyt and Daniel Domingo-Fernández at the Fraunhofer SCAI Department of Bioinformatics with support from the IMI project, AETIONOMY. It is built on top of PyBEL, an open source project. Please feel free to contact us here to give us feedback or report any issues. Also, see our Publishing Notes and Data Protection information.

If you find BEL Commons useful in your work, please consider citing: Hoyt, C. T., Domingo-Fernández, D., & Hofmann-Apitius, M. (2018). BEL Commons: an environment for exploration and analysis of networks encoded in Biological Expression Language. Database, 2018(3), 1–11.

---